David A. Weber
Director/Board Member at Oculis SA
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Thorsteinn Loftsson | M | - |
Oculis SA
 Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | - |
| Riad Sherif | M | 56 |
Oculis SA
Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | 7 years |
| Anthony Adam Rosenberg | M | 71 |
Oculis SA
Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | 6 years |
| Henry Skinner | M | 60 |
Oculis SA
Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | - |
| Árni Blöndal | M | - |
Oculis SA
Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | - |
| Lionel Carnot | M | 56 |
Oculis SA
Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | - |
| Robert Hopfner | M | 51 |
Oculis SA
Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | - |
| Bart Dzikowski | M | - |
Oculis SA
Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | - |
| Jim Branch | M | - | 13 years | |
| Sylvia He | M | - |
Oculis SA
Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | - |
| Vanessa Huang | F | - |
Oculis SA
Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | - |
| H. Hogan | M | 61 | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jay Lichter | M | 62 | 15 years | |
| Eric Loumeau | M | 61 | 3 years | |
| George Morrow | M | 72 | 3 years | |
| Ciara Kennedy | M | 52 | 3 years | |
| Iain Robert McGill | M | 51 | 7 years | |
| Jill Broadfoot | F | 63 | 2 years | |
| Julie Burgess | F | - | 7 years | |
| Carla da Luz Boren | F | - | 6 years | |
| Peter Bisgaard | M | 50 | 5 years | |
| Theodore Schroeder | M | 69 | 8 years | |
| Chau Khuong | M | 48 | 3 years | |
| Heather Elizabeth Preston | M | 58 | 10 years | |
| John McKearn | M | 70 | 5 years | |
| James Breitmeyer | M | 70 | 5 years | |
| Vickie Capps | F | 62 | 9 years | |
| Brian H. Dovey | M | 83 | 5 years | |
| Jeffery J. Anderson | M | - | - | |
| Breianna Bowen | F | - | 7 years | |
| Fabrice Piu | M | - | 15 years | |
| David Skarinsky | M | - | 2 years | |
| Erik Nelson | M | - | - | |
| Alan C. Foster | M | - | 8 years | |
| Dean Hakanson | M | 72 | 3 years | |
| Jessica Oien | F | 53 | 3 years | |
| Joel Naor | M | - |
MacuSight, Inc.
 MacuSight, Inc. Pharmaceuticals: MajorHealth Technology MacuSight, Inc. develops and manufactures pharmaceuticals products. The firm engages in developing therapeutics for the treatment of severe ocular diseases and conditions. It offers sirolimus, a therapeutic for the treatment and prevention of wet age-related macular degeneration, as well as for the treatment of diabetic macular edema; and related compounds and other select therapeutics in the eye, as well as minimally-invasive ocular formulations. The company was founded in 2003 and is headquartered in Union City, CA. | 2 years |
| Cindy Berejikian | F | - | - | |
| G. Michael Wall | M | - | - | |
| Katherine Bishop | M | 58 | 2 years | |
| Anthony J. Yost | M | 65 | - | |
| Robert Michael Savel | M | 56 | 8 years | |
| Barbara M. Finn | F | - | 10 years | |
| Carl LeBel | M | 65 | 7 years | |
| Gerald J. Wroblewski | M | - | - | |
| Tiba Aynechi | M | 48 | 4 years | |
| Mark Blumenkranz | M | 73 |
MacuSight, Inc.
MacuSight, Inc. Pharmaceuticals: MajorHealth Technology MacuSight, Inc. develops and manufactures pharmaceuticals products. The firm engages in developing therapeutics for the treatment of severe ocular diseases and conditions. It offers sirolimus, a therapeutic for the treatment and prevention of wet age-related macular degeneration, as well as for the treatment of diabetic macular edema; and related compounds and other select therapeutics in the eye, as well as minimally-invasive ocular formulations. The company was founded in 2003 and is headquartered in Union City, CA. | - |
| Stefán Jökull Sveinsson | M | - |
Oculis SA
Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | - |
| Anna Stepannenko | F | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 38 | 77.55% |
| Switzerland | 11 | 22.45% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- David A. Weber
- Personal Network
